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ABSTRACT
Cardiovascular disease remains the number one cause of mortality worlwide. Heart failure
occurs when the heart does not meet the body’s demand. Although significant medical advances
have been made, 50% of heart failure patients still die within five years of prognosis, suggesting
the need for more research. Alterations of inhibitor-1 (I-1) levels and activity have been associated
with heart failure. I-1 PKA-mediated phosphorylation activates its inhibitory activity against PP1,
which leads to calcium re-uptake into the sarcoplasmic reticulum (SR). Calcium mishandling plays
an important role in cardiac diseases, such as heart failure. Since I-1 is at the top of this signaling
pathway, attention has been giving into the function of I-1 in heart failure. AKAP18, a major
cardiac scaffold, organizes a multimolecular complex comprised of I-1 and other signaling
proteins, which allows the scaffold to regulate Ca2+ reuptake into the SR. Our lab was interested
in looking into the binding between AKAP18 and I-1.
Our immunoblot analysis with AKAP18 siRNA showed that I-1 was not phosphorylated
(by PKA) when AKAP18 was silenced. Previous worked from the lab narrowed the I-1 binding
domain to the 1-75 segment of AKAP18 (unpublished work). Our lab looked into this further
through protein pulldowns, which showed that I-1-GST immunoprecipitated with AKAP18(175). Furthermore, I-1 and AKAP18(1-75) are highly unstructured, which motivated us to study
their binding structurally through NMR spectroscopy. Our 2D 1H-15N-Heteronuclear Single
Quantum Coherence (HSQC) titration experiment showed that AKAP18(1-75) remained
disordered when titrated with I-1. But there were several chemical shifts perturbations in the HSQC
spectrum, the most noticeable being a glycine residue we hypothesize to be Gly28. Chemical shift
perturbations could be indicative of binding, suggesting the Gly28 might be part of the I-1 binding
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domain. Defining the AKAP18/I-1 binding domain can lead to the generation of reagents that
disrupt their binding, which could help understand the role of AKAP18/I-1 binding in heart failure,
and could open the door to new therapeutic approaches.

xii

CARDIOVASCULAR DISEASE
The heart is a major muscular organ that plays a vital role for human health. As part of the
cardiovascular system it pump blood to the rest of the body, supplying peripheral organs and
tissues with oxygen and nutrients [8, 9]. Defective heart function has disastrous effects on the
human body, and over the years the number of heart disease patients have escalated [1]. According
to the American Heart and Stroke Association 2018, cardiovascular disease remains the leading
cause of mortality worldwide, claiming more lives than all forms of cancer and Chronic Lower
Respiratory Disease combined. In the US, around 2,300 people die of heart disease each day, this
averages to 1 death every 38 seconds. Direct and indirect costs of heart disease and stroke is more
than $329.7 billion, including both health expenses and lost productivity [1].
Around 9% of the deaths caused by cardiovascular disease can be accredited to heart failure
(Figure 1) [1, 9, 10]. Heart failure mortality rates vary between gender (males have higher mortality
rates) and racial/ethnic groups (Non-Hispanic Blacks have higher mortality rates) (Figure 1). In
the US, approximately 6.5 million people suffer from heart failure, and that number is expected to
grow 46% from 2012-2030 [1]. Heart failure occurs when the heart’s pumping ability is damaged
and cannot meet the body’s demand for blood, oxygen and nutrients [1, 9, 10]. This decline in the
heart’s pumping efficiency and is marked by an interplay between defective cardiomyocyte
function and compensatory mechanisms that try to increase the cardiac output, and meet the body’s
demand [6].
One of these mechanism is done by the sympathetic (adrenergic) nervous system. Initially,
to compensate for decreased cardiac output due to, e.g. myocardial infarction, the sympathetic
nervous system is activated, stimulating

-adrenergic signaling which leads to an acute
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improvement in cardiac output. But long-term -adrenergic stimulation can lead to adverse effects
on the heart, resulting in decompensation and progressive worsening of the heart function (Figure
2) [6]. Even though many new drugs to treat heart failure have been developed over the years, such
as -blockers, coronary revascularization, angiotensin-converting enzyme (ACE) inhibitors,
implantable cardioverter- defibrillators, among others [1], the mortality rate of heart failure
remains 50% within 5 years [11]. Marking the need for the development of better therapeutic
interventions for heart failure.

Classifications of Deaths Due to Cardiovascular Disease

HF Death Rate
per 100,000

Males Females

NH White

107.4

79.6

NH Blacks

112.6

83.9

NH Asians or
Pacific Islanders

47

33.3

NH American
Indians or
Alaska Natives

100.9

75

Hispanics

67.5

48.8

Figure 1. Cardiovascular disease statistics. Pie chart illustrating the breakdown
of deaths accredited to cardiovascular disease and age-adjusted mortality rates for
heart failure (HF) per 100,000 (2015 statistics).
[1]
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a

Figure 2. Heart Failure cycle of events. Diagram depicting how the sympathetic nervous
system and -adrenergic receptors work to improve cardiac output. Long-term stimulation of
this compensatory mechanism result in progressive worsening of cardiac function. [6]
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A-KINASE ANCHORING PROTEINS (AKAPS)
In order to better treat heart failure, it is necessary to study the heart at the cellular level.
And one of the key compensatory mechanisms of the heart in response to stress is activation of
sympathetic nervous system and -adrenergic receptors. The cardiomyocyte is equipped with adrenergic receptors that can bind to the agonists (e.g. norepinephrine) released as a result of stress
[6].This binding results in a confirmational change and the activation of a small G-protein which
then activates adenylyl cyclase (AC), an enzyme that generates cAMP. The main target of cAMP
is Protein Kinase A or PKA. PKA is a serine/threonine kinase with broad specificity, composed of
a regulatory dimer, with each regulatory subunit binding a catalytic subunit. When two molecules
of cAMP bind to each regulatory subunit, a confirmational change occurs and the catalytic is
released and can phosphorylate substrates (Figure 3A) [12].
Extensive research has shown PKA activity is a critical component to heart disease
development [13]. However, because PKA has so many targets, it has become clear that
localization of this kinase to the right place in the cell, at the right time, is necessary. This is
accomplished via scaffold proteins known as A-Kinase Anchoring Proteins or AKAPs. These
scaffolds work by forming protein complexes and coordinating signaling activity, which provides
specificity and efficiency [14]. More than 50 AKAPs have been identified including splice variants
[12, 15]. Although AKAPs differ structurally [12, 14], they collectively work as scaffolds, bringing
proteins in close proximity to their targets, facilitating their signaling transduction.
And there are a few criteria used to characterize proteins as AKAPs. First, a major feature
is their conserved amphipathic helix, around 14-18 residues long, that form the PKA binding
domain, which gives AKAPs the ability to anchor the regulatory subunits of PKA in close
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proximity to its targets (Figure 3B) [15, 16]. Another important feature of AKAPs, is their ability
to anchor signaling molecules to specific subcellular localization through a targeting sequence
(Figure 3B). Different types of AKAPs have been localized at the endoplasmic reticulum,
mitochondria, nuclear membrane, plasma membrane, and dendrites, among others, through
fractionation and immunohistochemical analysis [14]. Furthermore, AKAPs anchor enzymes not
just to specific organelles, but also facilitate protein activation through specific pools of signaling
molecules. Different localized pools of cAMP were first shown in the late 1970s, when two
different G-protein coupled receptor agonists increased cAMP in the heart, but only one of them
increased glycogen phosphorylase activity and heart contraction [17, 18]. Since PKA is a major
target of cAMP, AKAPs anchor cAMP-mediated events to specific subcellular compartments. This
not only organizes cAMP signaling processes but also separates signaling pathways within the
same compartment, providing spatial and temporal control [14].
AKAPs are also multivalent (Figure 3B), capable of anchoring a variety of signaling
molecules including kinases, phosphatases, small GTPases, phosphodiesterases, adenylyl
cyclases, transmembrane receptors, transcription factors and ion channels [19, 20]. This feature
gives AKAPs the ability to bring signaling complexes to specific compartments inside the cells.
Overall, AKAPs allow specificity, localization and spatiotemporal control of signaling events
throughout the human body. And over the years, researchers have diverted their attention to
investigating how anchored signaling pathways are impaired in disease, bringing AKAPs and its
binding partners to the table as potential therapeutic targets.
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C
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Figure 3. -adrenergic signaling and AKAP features. A) Diagram illustrating adrenergic signaling. B) AKAPs contain 3 crucial features: 1. A conserved amphipathic
helix, that allows binding of the regulatory subunits of PKA. 2. AKAPs are capable of
anchoring many different signaling molecules. 3. AKAPs carry targeting sequences that
allow the anchoring of entire signaling complexes to specific subcellular localizations.
B) Diagram illustrating -adrenergic signaling [6].
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AKAPS IN THE HEART
AKAPs ability to form localized multiprotein complexes lead researchers to investigate the
role of scaffolds in the induction of heart disease. Around 17 AKAPs have been discovered in the
heart [21] (Table 1). Localized at specific subcellular compartments, they regulate many cardiac
functions including heart rhythm, action potential duration, calcium movement, cardiac
contraction and relaxation, as well as play an essential role in homeostasis, adaptation and
pathophysiology [22]. Among the AKAPs present in the heart, AKAP18 remains one of the
scaffolds most studied. AKAP18 resides both in the plasma membrane and sarcoplasmic
reticulum, facilitating calcium cycling, controlling cardiac contraction and excitation [15].
Yotiao, also known as AKAP 9, coordinates a protein complex around KCNQ1 potassium
channel. Regulation is enabled through kinases, phosphodiesterases and phosphatases that are
anchored to yotiao, to ensure proper function of the channel. Disrupting the binding between yotiao
and KCNQ1 was shown to lead to cardiac arrhythmias [23-25]. AKAP79 is another scaffold that
binds and regulates L-type calcium channels [26]. AKAP-lbc was shown to coordinate protein
kinase D (PKD1), an important kinase in cardiac remodeling [27, 28]. AKAPs have also been
reported in the nucleus (mAKAP and AKAP95), where they facilitate and intrinsically control
nuclear signaling [20, 23, 29]. There are many other AKAPs in the heart [23], and their capability
to provide spatio-temporal control of entire signaling complexes could give insight into the
mechanism of action of cardiovascular diseases, opening the doors for novel therapeutic
approaches.
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Table 1. Common AKAPs in the heart.
Gene Name

Protein Name

Localization

References

AKAP1

D-AKAP1/2

Outer mitochondrial
membrane

[30, 31]

AKAP5

AKAP79

Plasma membrane

[26, 32, 33]

AKAP6

mAKAP

Nuclear envelope

[34, 35]

AKAP7

AKAP15/18

Plasma membrane &
sarcoplasmic reticulum

[5, 36]

AKAP8

AKAP95

nucleus

[23, 29]

AKAP9

yotiao

KCNQ1 potassium channel

[23, 24]

AKAP12

gravin

2AR

[37]

AKAP13

AKAP-lbc

Actin cytoskeleton

[38, 39]
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PROTEIN PHOSPHATASE INHIBITOR-1 (I-1)
AKAPs target PKA to its substrates in order to increase specificity and efficiency in cardiac
signaling, motivating reserachers into studying Inhibitor-1 (I-1), a PKA phosphorylation target in
cardiomyocytes. I-1 was first reported in the late 1970s and was identified as the first endogenous
inhibitor of PP1. I-1 is expressed in all mammalian tissues with the highest expression in pancreas,
brain skeletal muscle, heart muscle and kidneys. I-1 is a disordered, soluble protein (~19kDa, 171
amino acids) comprised of many charged amino acids, e.g. proline and glutamate. It is highly
stable to heat, low pH organic solvents and detergents [3, 7]. Sequence homology between rat and
rabbit tissues showed that its NH2-terminus region (~ first 50 amino acids), which includes its
PKA-mediated phosphorylation site (Thr35), are highly conserved, whereas its COOH-terminus
showed more variability [40]. Up to this date, only three I-1 phosphorylation sites have been
proven experimentally: Thr35, Ser67 and Thr75. Phosphorylation at Thr35, by PKA, activates I-1
inhibitory activity against PP1, while phosphorylation at Ser67 and/or Thr75 by PKC suppresses
I-1 inhibitory activity. I-1 activation is also regulated by phosphatases, PP2A and PP2B
dephosphorylate I-1 at Thr25 (Figure 4) [3, 7].
PP1 is a major cardiac protein phosphatase, and inhibition of PP1(by I-1) leads to Ca2+ reuptake into the sarcoplasmic reticulum (SR), a huge calcium store [2, 3]. Calcium reuptake is
required for cardiac relaxation. Interestingly, calcium cycling dysregulation is a hallmark of heart
failure [41]. Increased PP1 activity has been linked to heart failure in human and rat models.
Furthermore decreased I-1 levels and decreased phosphorylation of I-1 (at Thr35) has been
reported in human hearts and animal models as well [3]. So because excessive PP1 activity,
possibly caused by lack of I-1 function, may contribute to heart failure and possibly other heart
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diseases, means that a more complete understanding of the function of I-1 in the heart is needed,
to provide better therapeutic approaches. Additionally, the fact that AKAPs work by forming
multiprotein complexes, which includes PKA and its targets raised the following question in the
cardiac field: Does I-1 bind to an AKAP in the heart? This question was discussed and investigated
by Singh and colleagues a few years back. Through rat heart incubations, pulldown assays and
western blots they found that I-1 binds directly to AKAP18 [4].

PP2A

PP2B
De

N-terminus

KIQF
1

9

ac
tiv
at
io

Activation

n

PKCα

PKCα

PKA

Deactivation

P

P

P

Thr
35

Ser
67

Thr
75

12

Conserved among
vertebrate species

50

C-terminus
171

PP1

SERCA2 pump

Figure 4. Schematic illustration of Inhibitor-1 (I-1), with known binding domains and
phosphorylation sites. The first N-terminus 50 amino acid are conserved among different
vertebrate species, while the C-terminus contains more variability. The KIQF motif of I-1
mediates its binding with PP1. The three phosphorylation sites (Thr35, Ser67 and Thr75)
regulate its activity. PKA-mediated phosphorylation of Thr35 activate its inhibitory activity
towards PP1, promoting Ca2+ reuptake into the SR through the SERCA pump. PP2A and
PP2B deactivate this signaling by dephosphorylating I-1 at its Thr35 site. Another way of
deactivating I-1 activity is through PKC-mediated phosphorylation of Ser67 and/or Thr75.
Deactivation of I-1 inhibitory activity promotes PP1 activation which result in SERCA2
pump inhibition.
[7]
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AKAP18
AKAP18 is highly expressed in the brain and the heart [23]. Encoded by the AKAP7 gene,
it produces 4 known splice variants: alpha, beta, gamma and delta (Figure 5). AKAP18 (also
known as AKAP15), is a 18 kDa protein derived from the smallest transcript variant. It is targeted
at the plasma membrane of cardiomyocytes and skeletal muscle cells [42] through myristoylation
and palmitoylation of its N-terminus, giving AKAP18 the ability to regulate L-type calcium
channel (LTCC) after AR stimulation [15]. Studies in skeletal muscle cells showed that
AKAP18 interacts with LTCC through C-terminal domain of the 1 subunit of LTCC [43].
Although these calcium channels are mainly voltage- dependent, channel activity is potentiated by
phosphorylation of AKAP18 -bound PKA (Figure 6A) [42, 44]. Disruption of AKAP18 and
LTCC binding in mice showed loss of sensitivity to cAMP stimulation, and lead to cardiac
hypertrophy [23].
AKAP18, a 20kDa protein, is structurally and functionally similar to AKAP18. The
additional 24 amino acids facilitate its binding to the apical membrane of polarized epithelial cells,
and further investigations are needed to address AKAP18 function at these sites [36]. Not only
does AKAP18 coordinate calcium movement at the plasma membrane, but its longer isoforms
AKAP18 ( and ) are localized at the sarcoplasmic reticulum. Sarcoplasmic reticulum Ca2+ATPase (SERCA2) plays an essential role in calcium cycling by coordinating calcium re-uptake
into the sarcoplasmic reticulum. Lygren and colleagues

showed that AKAP18 forms a

signalosome containing PKA, phoshpolamban and SERCA2. Phospholamban (PLB) is a negative
regulator of the SERCA2 pump. In its dephosphorylated state PLB binds to SERCA2 and inhibits
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calcium re-uptake into the sarcoplasmic reticulum. SERCA2 suppression is blocked when PLB is
phosphorylated by PKA at Serine 16 (Figure 6B) [5].

Figure 5. AKAP18 splice variants [4].

Dysregulation of SERCA2 and PLB activity has been connected heart failure [5].
Moreover, there are other molecules associated with the other long isoform, AKAP18: protein
phosphatase 1 and inhibitor-1, that further control the SERCA2 pump [4]. Singh and colleagues,
identified the long isoform AKAP18 as the scaffold that directly binds to I-1[4]. They were also
able to show that AKAP18 binding to PKA faciliatates I-1 phosphorylation, as well as PP1
inhibition, showing the importance of the scaffold in these signaling events. Displacement of PKA
from AKAP18 attenuated I-1 phosphorylation at Thr 35 site, therefore preventing the effective
inhibition of PP1 activity [4] This finding prompted our lab to study the the significance of
AKAP18 and I-1 binding in I-1 phosphorylation. Marking the first question this project wanted
to address: Is AKAP18/I-1 binding important for I-1 PKA-mediated phosphorylation?
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Ca2+
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AKAP18α
PKA
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Figure 6. Schematic drawing of AKAP18 role in Ca2+ cycling. A) The shorter isoform,
AKAP18, is targeted to the plasma membrane through myristoylation and palmitoylation,
where it facilitates L-type Calcium Channel (LTCC) phosphorylation increasing its
conductance. B) The longer isoforms AKAP18 ( and ) are targeted to the sarcoplasmic
reticulum (SR) where they form a protein complex comprising of sarcoendoplasmic
reticulum calcium ATPase 2 (SERCA2), phospholamban (PLB), PKA, protein phosphatase
1 (PP1) and inhibitor-1 (I-1). AKAP18 / orchestrates PKA-mediated I-1 phosphorylation,
which activates I-1 inhibitory activity against PP1, maintaining PLB in its phosphorylated
form resulting in SERCA2 activation and subsequent movement of Ca2+ into the SR.
[2-5]
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METHODS
AKAP18 siRNA
For siRNA experiments neonatal rat cardiomyocytes, transfected with AKAP18 siRNA, were
stimulated with 100nM isoproterenol for 5 minutes. Immunoblots to determine I-1
phosphorylation were done with a phospho-specific antibody which recognizes Thr35, the I-1
residue phosphorylated by PKA.
Protein Purification
For protein purification assays, LB cultures were started with the gene of interest. The vectors used
were I-1-GST, AKAP18(1-75) pET15b and I-1 pET15b. Protein expression was induced with
1M IPTG for 5 hours. Cultures were centrifuged for 5 minutes at 6,000 rpm and the pellets were
frozen for 1 hour. Frozen pellets were thawed and lysed with 1M PMSF and either binding buffer
(20mM HEPES, 0.5mM NaCl, pH 7.4) or GST buffer (recipe below). Binding buffer was used to
purify His-tagged proteins and GST buffer was used to purify GST-tagged proteins. The lysate
was left rocking at 4C for 5 hours. Afterwards lysate is centrifuged for 15 minutes at 8,000 rpm,
and the collected supernatant is incubated with its respective beads overnight. For His-tagged
proteins, Ni beads were used and for GST-tagged proteins GST beads were used. The beads are
washed 3X with its respective buffer, ran through SDS-PAGE and stained with Coomassie Blue.
Western blots were also performed on the samples (antibody that recognize the His tag of
AKAP18 and an I-1 antibody) to ensure that our proteins of interest were expressed.
Protein Pulldowns
For protein pulldown experiments, the 1-75 segment of AKAP18 (His-tagged) was bacterially
expressed, purified, and Ni beads were stripped off with 1M Imidazole. AKAP18 (1-75) was
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incubated overnight with bacterially expressed and purified I-1-GST (GST beads were used to
pulldown the 1-75 segment of AKAP18). Binding between the AKAP18(1-75) and I-1 was
determined through western blot with a His antibody that recognized the His tag on the
AKAP18(1-75) protein. GST beads (with a GST tag) were used as controls and protein pulldown
experiments were done in triplicate. Input were also used as controls, to ensure AKAP18(1-75)
expression in control experiments.
NMR Spectroscopy
To prepare protein samples for NMR,

15N-labeled

AKAP18(1-75) pET15b and unlabeled I-1

pET15b proteins were bascterially expressed, purified and stripped off their Ni beads with 1M
Imidazole. They were both dialyzed to a NMR appropriate binding buffer (20mM, 100mM NaCl,
pH 7.0) and concentrated (15N-labeled AKAP18(1-75) - 0.3mM and unlabeled I-1 - 1.52mM)
using Amicon® Ultra-4 Centrifugal Filter Units. Before concentrating, 1M DTT was added to I-1
pET15b and AKAP18 (1-75) pET15b samples at 1:1,000 dilution, to avoid AKAP18(1-75)
dimerization. To study the interaction of 15N-labeled AKAP18(1-75) and unlabeled I-1, a twodimensional 1H-15N-HSQC titration experiment was performed on a 500 MHz NMR spectrometer.
15N-labeled

AKAP18(1-75) (0.3mM) was titrated with unlabeled I-1 (1.52mM) at a 1:0.6, 1:1 and

1:2.5 ratio. All NMR spectra were processed and analyzed using NMRbox software and the
glycine chemical shift perturbation was further analyzed through the TITAN software. All NMR
experiments were performed at 25C .

15

PSIPRED 3.3
The primary amino acid sequence of the 1-75 segment of AKAP18 and I-1 was inserted into the
PSIPRED 3.3 software to predict their respective secondary structure.

GST Buffer Recipe
50 mls 100% glycerol
5 mls Triton X-100
25 mls 1M Tris pH 8.0
15 mls 5M NaCl
5 mls EDTA
400 mls H20
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RESULTS
Previous work demonstrated that PKA displacement from AKAP18 attenuated I-1
phosphorylation at Thr 35 site, therefore preventing the effective inhibition of PP1 activity [4].
The importance of AKAP18 and PKA binding prompted our lab to study the significance of
AKAP18 and I-1 binding in I-1 phosphorylation. Neonatal rat cardiomyocytes were transfected
with an AKAP18 siRNA, stimulated with isoproterenol (100nM) for 5 minutes and I-1
phosphorylation was determined by western blot with a phospho-specific antibody that recognizes
Thr35 site (I-1 residue phosphorylated by PKA). Immunoblot results showed that isoproterenol
stimulation did not phosphorylate I-1 in the cells that were transfected with AKAP18 siRNA,
compared to control siRNA where I-1 phosphorylation, through isoproterenol stimulation, was
observed (Figure 7A). These results suggests that AKAP18 and I-1 binding might be required for
I-1 phosphorylation, which is supported by literature depicting AKAP18 as a scaffold orchestrating
signaling activity between its binding partners [4, 5].
The possibility that AKAP18 and I-1 might be crucial for I-1 phosphorylation motivated
our lab to look into the binding domain of AKAP18 and I-1. Previous mapping work had narrowed
down AKAP18/I-1 binding domain to the 1-75 segment of AKAP18 (unpublished work), this was
further studied through protein pulldowns. The 1-75 segment of AKAP18 (His-tagged) was
bacterially expressed and purified, Ni beads were stripped off with Imidazole. AKAP18(1-75)
was incubated with bacterially expressed and purified I-1, which was tagged with GST (Figure7B).
The binding between the 1-75 segment of AKAP18 and I-1 was determined through western blot
with a His antibody that recognized the His tag on the 1-75 segment of AKAP18. Results showed
that AKAP18(1-75) precipitated only with I-1-GST, and not to the GST tag alone, further
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demonstrating the specificity of the binding between the 1-75 segment of AKAP18 and Inhibitor1 (Figure 7C).

A.

Iso (100 nM):

+

AKAP18 siRNA:
control siRNA:

+
+

+

+

+

IB: AKAP18

IB: Phospho-I-1

IB: I-1

B.
1-75 AKAP18-His

I1-GST
1-75 AKAP18-His
I1-GST

GST

GST control
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C.

GST-I1

GST
control

Figure 7. AKAP18/I-1 binding is required for I-1 phosphorylation and I-1 binds to the
1-75 segment of AKAP18. A) Rat neonatal cardiomyocytes transfected with AKAP18
siRNA and stimulated with isoproterenol (100nM) showed no I-1 phosphorylation, compared
to control siRNA. B) Diagram illustrating the purified protein pulldown experiment. C)
Western blot showing that purified AKAP18(1-75) His-tagged only precipitated with GSTtagged I-1, and not with the GST tag alone. His antibody was used to determine binding.
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AKAP18/INHIBITOR-1 BINDING DOMAIN
Our lab wanted to look even further, we were interesting in knowing what region I-1 binds
to the 1-75 segment segment of AKAP18. This marks the second question this project wanted to
address: defining the binding domain between I-1 and the 1-75 segment of AKAP18. Although
I-1’s tight regulation has been the subject of many studies, it’s I-1 protein structure that gained
attention over the years. I-1 is a disordered, comprised of many charged amino acids [7]. An
interesting fact about AKAP18 is that it N-terminus region is predicted to be disordered as well
[45]. Unstructured proteins can also be referred as intrinsically disordered proteins (IDPs) or
intrinsically disordered regions (IDRs) [46, 47]. In the past research was guided by the common
concept that a protein’s function is closely related to its 3D structure, which still remains true. But
over the years, it has been found that certain proteins don’t fit this common criteria [46].
These proteins called Intrinsically Disordered Proteins (IDPs), they function even though
they lack tertiary contacts and usually do not have stable secondary structure. They lack bulky
hydrophobic residues (e.g. valine, leucine, tryptophan, among others) which usually form the
hydrophobic core of folded proteins. These IDPs are dynamical and flexible, which permits them
to adopt distinct conformations upon binding to different partners [46, 47]. A paper paper
published a few years ago looked at the binding between PP1 and another inhibitor called
Spinophilin. Spinoliphin is a neuronal regulatory protein that targets PP1. Since PP1 regulates
neuronal synapse, Spinophilin plays an important role in learning and memory.

And the

Spinoliphin PP1-binding domain is highly unstructured. After performing NMR in these proteins
they found out that Spinophilin folds when binding to PP1[48].
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There is a direct interaction between I-1 (IDP) and the 1-75 segment of AKAP18 (IDR).
And the fact that these disordered proteins may adopt different conformation (even fold) upon
binding to other proteins, suggest that the 1-75 segment of AKAP18 might do the same upon
binding to I-1. And that's the third question our lab wanted to address. Does the 1-75 segment of
AKAP18 fold upon binding to I-1? So these are the last two questions this project wanted to
elucidate. First, our lab was interested in pinpointing the I-1/AKAP18 binding domain. Second,
since the 1-75 segment of AKAP18 is disordered, we are curious to find out if AKAP18(1-75)
folds upon binding to I-1, another disordered protein, as suggested by literature [46, 47]. Both
questions were addressed through protein purifications (Figure 8A and B) and NMR spectroscopy.
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overnight
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Freeze Pellets
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Add
beads
Rock at 4oC
overnight
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Centrifuge and
collect supernatant

Run Gel and Stain

Rock at 4°C for 5
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Strip from Beads

PMSF
Thaw pellets in
Lysing Buffer

NMR
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B.
25
20
15
10
AKAP18
I-1
(1-75)
pET15b
pET15b

Figure 8. Illustration of protein purification assays and protein stain of AKAP18 (175) and I-1. A) Bacterially expressed proteins are purified and stripped from its beads
according to the illustration above (for more information see Methods). B) Protein stain of
AKAP118(1-75) and I-1, stripped from its beads.
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NMR SPECTROSCOPY RESULTS
First, we wanted to observe the unbound structure of the 1-75 segment of AKAP18, so
15N-labeled

AKAP18 (1-75) was bacterially expressed, purified and stripped off its beads (Figure

8A and B), to then analyze by NMR. The two dimensional 1H- and

15N-

Heteronuclear Single

Quantum Coherence (HSQC) spectrum showed that the 1-75 segment of AKAP18 was indeed
unstructured, which is characterized by crowded and narrow peaks in the 1H dimension (Figure
9A). The structure of the 1-75 segment of AKAP18 was also looked at through PSIPRED 3.3
protein structure prediction server, which can predict secondary structures from its amino acid
sequence alone. PSIPRED accuracy is measured by Q3 scores, which calculates the percentage of
residues predicted correctly and the PSIPRED 3.2 achieved a Q3 score of 81.6% [49].
Its results showed that there is a high confidence of prediction for a helix between residues
of 49 through 56, and a beta sheet between amino acids 67 and 68 of AKAP18(1-75). All other
helixes predicted have a low confidence of prediction, suggesting that this segment of AKAP18
is unstructured (Figure 9B), which supports our HSQC results on unbound AKAP18 (1-75). We
also looked into the structure of I-1 through the PSIPRED server (Figure 10), and the results
showed only two helixes (residues 22-32 and 81-92) with high confidence of prediction and the
majority of the rest of the I-1 protein was predicted to contain random coils (with high confidence
of prediction), which indicate lack of a stable secondary structure consistent with literature
depicting I-1 as a highly unstructured protein [3, 7].
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Figure 9. HSQC spectrum of the 1-75 segment of AKAP18 and PSIPRED 3.3 protein
structure prediction results of AKAP18 (1-75). A) Agglomerated and narrow peaks in the
1H dimension characterize the 1-75 segment of AKAP1 as an intrinsically disordered region.
B) PSIPRED results show high confidence of prediction for a helix (approximately residues
49-56) and a beta sheet (residues 67-68), the rest seems unstructured.

Figure 10. PSIPRED 3.3 results for I-1 protein structure prediction. PSIPRED 3.3
protein secondary structure server showed high confidence of prediction for two helixes and
random coils (which occupy the majority of the protein structure).
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It was also interesting to observe that one of the helixes predicted for I-1 was located
between residues 22-32. A previous study detected a transient helix between residues 22-29 of
dopamine- and cAMP-regulated phosphoprotein-32 (DARPP-32), another PP1 inhibitor with high
levels of amino acid sequence identity in the first 50 residues with I-1 [50, 51], demonstrating the
high efficiency of prediction of the PSIPRED 3.3 protein structure prediction server. After looking
into unbound AKAP18 (1-75), a two-dimensional 15N- and 1H- HSQC titration experiment (1:0.6,
1:1 and 1:2.5) was performed between

15N-labeled

AKAP18(1-75) and unlabeled I-1. Despite

research suggesting that intrinsically disordered proteins may fold upon interaction with binding
partners, our results showed that the structure of AKAP18 (1-75 ) remained disordered when
titrated with I-1 at a 1:0.6, 1:1 and 1:2.5 ratio (Figure 11).
Although our lab did not perform amino acid assignments, some residues reside in specific
locations in the HSQC spectrum e.g. tryptophan, glycine, asparagine and glutamine. Tryptophan
residues are located on the bottom left of the HSQC spectrum between ppm 10 and 11 at the 1H
dimension. Our lab observed only one peak which is consistent with the only tryptophan residue
in the 1-75 segment of AKAP18, Try45, where no changes were observed in the Try45 peak upon
I-1 titration (Figure 12A). Asparagine and glutamine side chain usually generate two peaks in the
same 15N dimension (between 110 and 115 ppm) but in different ppm values in the 1H dimension.
No changes were observed in neither of these peaks when titrated with I-1 at a 1:0.6, 1:1 and 1:2.5
ratio (Figure 11 and 12B). To answer one of our questions: does AKAP18(1-75) fold upon binding
to I-1? No, but there were several chemical shifts perturbations observed. And this is where our
lab starts addressing the other question: Defining the I-1 binding domain of AKAP18.
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Figure 11. Two-dimensional HSQC titration experiment. The overall structure of
15
N-labeled AKAP18 (1-75) remained disordered when titrated with I-1 at a 1:0.6 (top
panel, blue), 1:1 (middle panel, green ) and at a 1:2.5 (bottom panel, turquoise) ratio.
Unbound AKAP18 (1-75) is represented in red.
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One of them was located between ppm values 118-120 (15N dimension) and between ppm
values 8.2-8.6 (1H dimension). We clearly observed that two strong peaks of unbound 15N-labeled
AKAP18(1-75) disappear when titrated with I-1, and one strong peak appears upon titration with
I-1, most noticeable at 1:2.5 ratio (Figure 12C). The specifics of the observed peak changes need
to be studied further, to determine which amino acid residues undergo these chemical shift
perturbations. The other chemical shift perturbation was observed in the region were glycine
residues are located. One strong peak is observed in unbound 15N-labeled AKAP18(1-75) (shown
in red) and upon titration with I-1 (shown in turquoise) AKAP18(1-75) experienced a chemical
shift change in what our lab hypothesizes to be glycine 28, the only glycine residue in the 1-75
segment of AKAP18 (Figure 12D). Future work is needed to determine if this peak belongs to
Gly28 in the AKAP18 and not the other three glycine residues in the tag and linker of
AKAP18(1-75), used for the bacterial purification assays.
The location of this glycine residue (isolated from the agglomerated peaks in the middle of
the HSQC spectrum) permitted us to analyze this residue (possibly Gly28) through a software tool
called TITAN (TITration ANalysis) [52]. Through the HSQC spectrum and TITAN data we could
determine the rate of exchange of our titration experiment. During a slow exchange, a gradual
change in peak position occurs as one titrates the ligand in. In a fast exchange, the free peak signal
progressively disappears, and the bound peak signals appears in another position in the HSQC
spectrum [52, 53]. Our titration data suggest that in the Gly28 peak, and the changes in chemical
shifts observed in the middle of the HSQC spectrum, a slow exchange occurred as the free peak
signal (AKAP18 (1-75)) gradually disappeared when I-1 was titrated in, another peak signal
appeared (Figure 11 and 13A).
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Figure 12. Two-dimensional 15N- and 1H- HSQC titration experiment results (1:2.5
ratio). A) AKAP18(1-75) only tryptophan residue, Trp 45, did not undergo any changes
upon titration with I-1. B) No changes were observed in asparagine and glutamine side
chain peaks. C) Two strong peaks of unbound AKAP18(1-75) (red) disappeared and one
strong visible peak appeared upon titrating with unlabeled I-1. More research is needed to
identify the amino acids involved in these chemical shift perturbations. D) In the section of
the HSQC spectrum where glycine residues reside, another chemical shift perturbation was
observed, which we hypothesize to be Gly28, and could be indicative of binding. Red =
unbound HN-labeled AKAP18, turquoise = AKAP18(1-75) titrated with I-1 at a 1:2.5
ratio.
This change in chemical shift in the Gly28 peak was better studied through the TITAN
software, where we could observe the two different peak positions between free and bound
AKAP18 (1-75). A change in chemical shift was immediately observed when AKAP18(1-75)
was titrated at a 1:0.6 ratio, and the strongest bound peak signal was seen when AKAP18(1-75)
was titrated at a 1:2.5 ratio (Figure 11 and Figure 13A). The TITAN software is a novel software
used to study titration experiments. It can simulate HSQC and HMQC pulse programs and
researchers are able to fit their experimental data with a range of binding models. If the selected
model fits with experimental data it could give insight into the binding mechanism, as well as
indicate the dissociation constant (K d) (11). The binding model that fit our titration data was a
simple two-state model and the dissociation constant (K d) given was 34 +/- 5 µM (Figure 13A).
The 3D viewer was used to observe and ensure that our titration data fit the binding model
selected. Our experimental titration data is represented in gray and the model data is represented
in red (Figure 13B). Chemical shifts perturbation could be indicative of binding. Although further
work is needed to identify the rest of the residues interacting directly with AKAP18 (e.g. amino
acid assignments, mutagenesis studies, etc.), our study provides the first step towards mapping the
I-1 binding site of AKAP18 and our lab proposes that Gly28 forms part of this binding domain.
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Overall, our data suggests that AKAP18/I-1 binding is crucial for I-1 phosphorylation (and I-1
activation), and defining their binding domain could give insight into the importance of
AKAP18/I-1 binding in calcium cycling and heart disease.
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Figure 13. TITAN software results. A) Detailed visualization of Gly28, in the HSQC
spectrum, as it undergoes a change in chemical shift when titrated with I-1 at a 1:0.6,
1:1 and 1:2.5 ratio. The dissociation constant (K d )provided from the TITAN software
was 34 +/- 5 µM. B) 3D viewer that indicated that our titration data (gray) fit the binding
model (red) provided through the TITAN software. P0= AKAP18(1-75) concentration,
L0= I-1 concentration.
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FUTURE STRUCTURAL AND MOLECULAR WORK
To our knowledge these are the first structural reports of AKAP18 and I-1 binding.
Although the 1-75 segment of AKAP18 remained disordered, the chemical shift perturbation
observed in a glycine peak on 15N labeled 1-75 AKAP18 surely sparked our interest. Chemical
shift perturbations in the HSQC spectrum could be indicative of binding. And our lab hypothesizes
that the chemical shift observed in the HSQC spectrum belongs to Gly28, since it is the only
glycine residue found in the 1-75 AKAP18 amino acid sequence, but there are three other glycine
residues found in its His tag and linker, which is why further work needs to be done (Figure 14).
Mutagenesis studies could be a great way to elucidate which glycine residue is causing this peak
change, e.g. mutating Gly28, with an alanine residue. After titrating the mutated (G28A)15Nlabeled 1-75 AKAP18 with unlabeled I-1, if no change occurs in the allotted space where Gly28
resides, then it would support our hypothesis that the observed peak change was indeed Gly28,
and not the glycine residues in the tag and linker.
The other chemical shift perturbations observed in our titration experiments could not be
analyzed through the TITAN software due to the agglomerated, narrow peak distribution in the
1H

dimension, which is characteristic of unstructured proteins. Furthermore, these chemical shift

changes did not occur in residues that have distinct localizations in the HSQC spectrum, which
would make them easy to identify, e.g. glycine or tryptophan. Therefore amino acid assignments
should be performed in the 1-75 segment of AKAP18 to properly identify all the amino acid that
acquire chemical shift perturbation when titrated with I-1. It would be interest to also perform
titrations of

15N-labeled

I-1 with unlabeled 1-75 AKAP18 to address any potential structural

changes on I-1 that may arise from I-1 and 1-75 AKAP18 binding.
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I-1 is an intrinsically disordered protein (IDPs), and their dynamic properties suggest the
possibility of I-1 folding and/or assuming a different confirmation upon binding to the 1-75
segment of AKAP18 [46, 47]. Many disordered proteins also undergo post-translational
modifications, which “can tune their conformational states and their interaction with their binding
partners” [46]. The structure of I-1 has been studied before and its conformation does not
experience any apparent change when phosphorylated at Thr35 [7]. Phosphorylation of Thr35 does
however increase its binding affinity towards native PP1 [54]. It would be interesting to see if I-1
phosphorylation at Thr35 has any effect on its affinity towards AKAP18.
Singh and colleagues demonstrated that although I-1 binds to an AKAP118 mutant (1268), which lacks the PKA binding site, I-1 phosphorylation (at Thr35 site) becomes significantly
attenuated in isoproterenol-stimulated HEK293 cells compared to I-1 phosphorylation when bound
to full-length AKAP18 [4]. So the lack of I-1 phosphorylation (by PKA) observed in our
immunoblots when AKAP18 was silenced by siRNA, not only could be due to the absence of
AKAP18-I-1 binding, but could also be partly caused by the absence of AKAP18-PKA binding.
Furthermore PKA activity is highly dependent on AKAP18 binding, the AKAP18 mutant (1268) lacked kinase activity, which explains the decreased phosphorylation at Thr35 site observed
in I-1 [4]. But I-1 is not the only PKA target in the multiprotein complex organized by AKAP18
in the SR. Phospholamban is another PKA substrate whose phosphorylation at Serine 16 releases
PLB’s inhibition towards SERCA2, thus activating the Ca2+ pump [5]. PKA also has substrates
outside the AKAP18/PLB/I-1/PKA complex at the SR. For example, Ryanodine Receptors
(RyRs) are major calcium release channels in the SR that are targets for phosphorylation by PKA
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[55]. PKA is also known to phosphorylate LTCCs, troponin I and myosin binding protein C, which
are all essential proteins for cardiac contraction [2].
Since there are multiple PKA substrates involved in cardiac function, silencing AKAP18
might attenuate PKA activity, affecting the modulation of its targets. This brings out the necessity
of defining the binding domain between AKAP18 and Inhibitor-1. Thanks to previous work, our
lab narrowed down the I-1 binding domain to the 1-75 segment of AKAP18 (unpublished work).
Defining AKAP18 I-1-binding domain could also clarify whether the chemical shift observed in
Gly28 (presumably) in our study is due to Gly28 direct binding to I-1 or if it’s a conformational
change induced by I-1 binding to residues nearby. Knowledge of its exact binding domain could
help investigate the structural implications/mechanism of AKAP18-I-1 binding. Does AKAP18
orchestrate I-1 phosphorylation (at Thr35) by placing I-1 in close proximity to PKA? Or does
binding to the scaffold induce a conformation change in I-1, exposing the site for PKA-mediated
phosphorylation? Addressing these questions could give insight into the mechanism of I-1
phosphorylation and activation at a structural level.

MGSSHHHHHHSSGLVPRGSHM M S E E F E A N T M D S L V D M P F
ATVDIQDDCGITDEPQINLKRSQENEWVKSDQVKK
RKKKRKDYQPNYFLSIPITNKE
Figure 14. Amino acid sequence of the 1-75 segment of AKAP18 in pET15b. The 175AKAP segment is highlighted cyan and the His tag and linker are represented with the
white box. Glycine residues are marked in bold and underlined, glycine 28 is marked in red.
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SIGNIFICANCE- DISRUPTOR PEPTIDE
After elucidating the exact binding domain between AKAP18 and I-1, it would be of great
interest to generate an AKAP18/I-1 disruptors peptide to study in more depth the importance of
this binding. Disrupting binding partners from AKAPs has been studied in the past especially with
AKAP-PKA disruptor peptides (10). But as mentioned before PKA has a vast number of
substrates, and disrupting PKA from AKAP18 might affect the phosphorylation of its many targets
[4]. And a major disadvantage of these peptide disruptors is that they do not interfere with a
specific complex, instead they disrupt all AKAP-PKA complexes [2]. Which is why attention has
been given to disrupting other AKAP18 binding partners, and why our lab focused on I-1.
AKAP18-I-1 disruptor peptides would only affect I-1 at the SR, which is an important element to
have in mind since I-1 has been reported to have targets at other cellular compartments outside the
SR [7].
I-1 has been associated with eIF2, a protein involved with protein synthesis, that has
been localized to the nucleus. Phospholemman and Na/K-ATPase, which are located at the plasma
membrane, are regulated by PP1 and I-1 in cardiomyocytes. I-1 expression has also been shown
in renal distal convoluted tubule, which is not a surprise since I-1 is also highly expressed in the
kidneys, and a study suggests it may regulate NaCl cotransporter (NCC) activity, a protein that
controls arterial blood pressure [7, 56-59]. Targeting the AKAP18-I-1 binding domain would only
interfere with the function of I-1 at the SR, without affecting its possible role at other
compartments.
AKAP18-I-1 disruptor peptides could be a great tool to study I-1 phosphorylation and its
inhibitory activity without affecting AKAP18 expression nor its ability to form protein complexes
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at the plasma membrane and at the SR level which facilitate calcium handling. Peptide disruptors
could also be used to perform PP1 phosphatase activity assays to correlate lack of I-1
phosphorylation (due to I-1 being displaced from AKAP18) with decreased PP1 phosphatase
activity, as one would expect since I-1 PKA-mediated phosphorylation activates its inhibitory
activity towards PP1 [7]. On a molecular level disrupting the binding between AKAP18 and I-1
could be used to observe the effects on I-1 phosphorylation and activity, PP1 phosphatase activity,
PLB phosphorylation state and SERCA2 pump activity (Figure 15A and B).
Additionally generating AKAP18-I-1 disruptor peptides could be of great use to study the
importance of this binding in calcium cycling. I-1 is known as a distal -adrenergic signaling
amplifier of PKA activity, being that phosphorylation of I-1 (by PKA) results in activation of
SERCA2 pump, followed by calcium re-entry into the SR. Defective calcium handling is observed
in cardiac arrhythmias, contractile dysfunction, heart failure, among other cardiac diseases [2].
Our results suggesting that AKAP18-I-1 binding is required for I-1 phosphorylation, might point
to AKAP18-I-1 disruptor peptides as a possible new model for defective calcium handling seen
in cardiac diseases (Figure 15A and B). Furthermore, I-1 levels and phosphorylation appeared
decreased in human failing hearts and heart failure mouse models. AKAP18-I-1 disruptor
peptides could help study in more depth the signaling mechanisms involved in heart failure, with
the intention of identifying targets that could lead to novel therapeutic approaches for heart failure,
as well as other cardiac diseases associated with impaired calcium cycling.
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Figure 15. A) Diagram illustrating how I-1 phosphorylation leads to calcium re-entry into
the SR under normal conditions. B) Diagram illustrating future possible studies with
AKAP18-I-1 disruptor peptides
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CONCLUSION
The heart is a major muscular organ that plays a vital role for human health. Defective heart
function has disastrous effects on the human body, and over the years the number of heart disease
patients have escalated, marking the need for new targets for therapeutic interventions. AKAP18
plays a critical role in calcium handling in the heart, at the plasma membrane and at the SR.
Calcium handling is critical for cardiomyocyte contraction and relaxation, and perturbation in
calcium cycling can result in heart disease [2]. Disturbed PLB and SERCA2 activity has been
associated with heart failure [5, 60]. The other binding partners of AKAP18 (at the SR) have also
been investigated, one of them being I-1, the upstream regulator of SERCA2 pump activity.
Altered I-1 levels and phosphorylation (at Thr35) have also been linked with heart failure, making
it a potential target for therapeutic approaches [3, 7].
I-1 has not been studied solely at a molecular level but its biochemical properties make I-1 an
interesting protein to study at a structural level as well, because I-1 is highly unstructured [3, 7].
Moreover, not only I-1 is an unstructured protein, but AKAP18 contains a disordered region (Nterminus)[45] and previous mapping studies narrowed down AKAP18/I-1 binding domain to the
1-75 segment of AKAP18 (unpublished work). Which brings out this interesting scenario where
an unstructured protein and an unstructured region interact, and literature suggest they might
undergo conformational changes (even folding) upon binding [46, 47].
Our lab started by first studying the importance of AKAP18/I-1 binding at a molecular level.
AKAP18 siRNA experiments showed that I-1 did not get phosphorylated in the cells where
AKAP18 was silenced and purified protein pulldowns demonstrated direct binding between I-1
and the 1-75 segment of AKAP18, suggesting that I-1 binding to AKAP18 may be crucial for I-1

39

phosphorylation and subsequent activation of its inhibitory function. These results motivated us
even more to study their interaction at a structural level through NMR spectroscopy. NMR results
showed that the 1-75 segment of AKAP18 (labeled with 15N) is in fact unstructured. And contrary
to what some people believed, the 1-75 segment of AKAP18 does not fold upon binding to I-1,
but it does experience some structural changes. Our most significant finding was a chemical shift
observed in the glycine region in the HSQC spectrum. Its isolated and clear signal permitted us to
analyze the chemical shift using the TITAN software.
Our lab hypothesizes that the glycine residue the underwent a chemical shift is glycine 28,
since it’s the only glycine residue in the 1-75 segment of AKAP18. Although further mutagenesis
studies will be needed in order to confirm that since there are three more glycine residues in the
His-tag and linker. Overall, these results mark the beginning of determining the I-1 binding
domain of AKAP18. The chemical shift perturbations observed in the HSQC spectrum of
AKAP18 (1-75) when titrated with I-1 can be indicative of binding, so there is a high probability
that Gly28 is part of the AKAP18/I-1 binding domain (Figure 16). Understanding the AKAP18-I1 binding domain at a structural level could lead to the development of disruptor peptides/reagents,
which could open the door to novel therapeutic approaches to combat calcium mishandling seen
in cardiac disease such as heart failure.

40

Figure 16. Illustration of part of AKAP18/I-1 binding domain. Our results suggest
that glycine 28 is part of AKAP18/I-1 binding domain, more studies are needed to
determine the rest of the residues involved in AKAP18 and I-1 binding. TBD = To Be
Determined.
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